Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors [0.03%]
HLX26新型抗LAG-3单克隆抗体单药或联合疗法在晚期实体瘤患者中的I期研究
Rujiao Liu,Hui Jing,Yang Chen et al.
Rujiao Liu et al.
Background: HLX26 is a novel, recombinant humanized anti-LAG-3 IgG4 monoclonal antibody that exhibits high affinity for LAG-3 and demonstrates that it can block LAG-3 and its ligand interaction and activate T cells in pre...
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis [0.03%]
OX40信号通路抑制作为特应性皮炎新治疗策略的作用机制研究
David Oliveira Dos Santos,Amir Mohamed,Adam Mohamed et al.
David Oliveira Dos Santos et al.
Atopic dermatitis is a chronic inflammatory skin disease affecting approximately 15-20% of children and 2-10% of adults worldwide. Epidermal barrier dysfunction and immune dysregulation are central to its pathogenesis, creating a self-perpe...
Kirk Hofman,Priyanka Jangied,Sathy V Balu-Iyer
Kirk Hofman
Gene and cell therapies have been gaining popularity with market approvals by the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies. Adeno-associated viral vector gene therapies approved for rare inheri...
Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases [0.03%]
针对年龄相关性疾病的影响核酸药物治疗学研究进展
Hyuk Gyoon Lee,Jinsil Kim,Chang-Young Jang et al.
Hyuk Gyoon Lee et al.
The rapid growth in the global aging population has intensified concerns regarding age-related diseases (ARDs), which pose substantial health and socioeconomic burdens. Current therapeutic strategies, such as small-molecule drugs, primarily...
Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential [0.03%]
条件激活的抗体平台：机制、模式及潜在临床转化能力
Namyeong Kim,Inchan Kwon
Namyeong Kim
Conditionally activatable antibodies represent a promising strategy to improve the therapeutic index of antibody-based drugs by restricting their activity to disease sites, thereby minimizing systemic toxicity. These engineered platforms le...
Correction: Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease? [0.03%]
纠正：血浆或白细胞中α-葡萄糖苷酶活性能否作为经典婴儿型庞培病未来基因治疗的生物标志物？
Martha C Faraguna,Daniël A M Lambregts,Ina Barzel et al.
Martha C Faraguna et al.
Hariz Mohamad Salleh,Farid Nazer Faruqu,Ajantha Sinniah et al.
Hariz Mohamad Salleh et al.
Nanocarriers (NCs) are nanosized delivery systems that can be engineered from lipids, polymers, inorganic compounds, viral structural proteins and extracellular vesicles to transport cargo efficiently. Their unique characteristics, includin...
Luís Cláudio Lima de Jesus,Rhayane Cristina Viegas Santos,Vasco Azevedo
Luís Cláudio Lima de Jesus
Mucositis significantly impairs patients' quality of life, and despite its clinical importance and the availability of symptomatic treatments, no gold-standard therapeutic protocol has been established. Recent advances in biotechnology and ...
Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease? [0.03%]
血浆或白细胞中α-葡萄糖苷酶活性能否作为经典婴儿型庞贝病的基因治疗生物标志物？
Martha C Faraguna,Daniël A M Lambregts,Ina Barzel et al.
Martha C Faraguna et al.
We studied alpha-glucosidase activity in plasma and leukocytes after an infusion of 40 mg/kg of recombinant alglucosidase alpha in patients with classic infantile Pompe disease to assess the pharmacokinetics and identify potential surrogate...
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection [0.03%]
基于官方数据收集的2016至2023年西班牙生物类似药的使用情况分析
Jaime Espin,Zuzana Špacírová,Leticia García-Mochón
Jaime Espin
Even though the use of biosimilar medicines is increasing across European countries, detailed and regularly published official data on biosimilar uptake are not publicly available except in Italy and Portugal. The main objective of this stu...